Related Experiment Video
Updated: Sep 7, 2025
Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
Published on: January 7, 2019
New therapeutic strategies based on biasing IL-2 mutants for cancers and autoimmune diseases
Dongfu Jin1, Yaxin Jiang1, Lu Chang1
1Department of Molecular and Cellular Pharmacology, Tianjin University, Tianjin 300072, PRChina.
Abstract:
Interleukin-2 (IL-2) is an immunomodulatory multifunctional cytokine. High-dose IL-2 was first approved by the U.S. Food and Drug Administration (FDA) in the 1990s for the treatment of metastatic renal cell carcinoma and metastatic melanoma. However, the short half-life of IL-2 and its toxicity caused by high-dose IL-2 limit the clinical use of IL-2. Recently, the development of cell-type-selective engineered IL-2 products become a hot research filed, mainly because IL-2 stimulates both regulatory T cells (Treg) and effector T cells (Teff) in vivo. The selective effect of IL-2 on Treg and Teff can be improved by designing biased IL-2 mutants, which showed reduced toxicity while being more effective in stimulating anti-tumor effector immunity or ameliorating autoimmune diseases. In this review we summarize the biological properties of IL-2 mutants reported so far. The design process and principle of IL-2 mutants, IL-2 mutant antibody complexes and IL-2 fusion proteins were discussed, which provided research basis for the design and application of IL-2 mutants in the future.
Insights
Engineered Interleukin-2 (IL-2) variants offer improved cancer and autoimmune disease treatments by selectively targeting T cells. These modified IL-2 proteins reduce toxicity while enhancing therapeutic efficacy.
Area of Science:
- Immunology
- Biotechnology
- Oncology
Background:
- Interleukin-2 (IL-2) is a cytokine with immunomodulatory functions.
- High-dose IL-2 is FDA-approved for metastatic melanoma and renal cell carcinoma but limited by short half-life and toxicity.
- IL-2 stimulates both regulatory T cells (Treg) and effector T cells (Teff), presenting a challenge for targeted therapy.
Purpose of the Study:
- To review the biological properties of engineered IL-2 mutants.
- To discuss the design principles of IL-2 mutants, antibody complexes, and fusion proteins.
- To provide a basis for future applications of IL-2 mutants in medicine.
Main Methods:
- Review of existing literature on IL-2 mutants.
- Analysis of design strategies for biased IL-2 variants.
- Discussion of IL-2 mutant antibody complexes and fusion proteins.
Main Results:
- Engineered IL-2 mutants can achieve cell-type selectivity for Treg and Teff cells.
- Biased IL-2 mutants demonstrate reduced toxicity compared to high-dose IL-2.
- Modified IL-2 products show potential for enhanced anti-tumor immunity and amelioration of autoimmune diseases.
Conclusions:
- Engineered IL-2 variants represent a promising therapeutic strategy.
- Selective IL-2 modulation offers a path to reduced toxicity and improved efficacy.
- Further research into IL-2 mutant design and application is warranted.
More Related Videos
09:15Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
Published on: February 24, 2023
07:55Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer
Published on: January 17, 2025
Related Concept Videos
01:27Tumor Immunotherapy
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:43Mouse Models of Cancer Study
The development of transgenic, knockout, and knock-in mice has led to an exponential increase in their use as model organisms in research,...